Naltrexone for the Treatment of Actively-Using Meth-Dependent MSM with High-Risk Sexual Behavior
Investigator: Eric Vittinghoff, PhD
Sponsor: Public Health Foundation Enterprises, Inc.
Location(s): United States
The investigators will enroll 100 sexually active, meth-dependent MSM who will be randomized 1:1 to receive monthly injections of extended-release naltrexone (n=50) or placebo (n=50) for 12 weeks at weeks 0, 4, and 8. Study participants will be seen weekly at our site at the HIV Prevention Section of the San Francisco Department of Public Health, where they will provide urine for drug testing and participate in substance use counseling. All participants will receive HIV risk-reduction counseling. Behavior will be assessed using standardized measures via audio computer-assisted self-interview (ACASI).